Bone-anchored hearing aid abutment skin overgrowth reduction with clobetasol.
Journal Article (Journal Article)
OBJECTIVES: The bone-anchored hearing aid (BAHA) osseointegrated cochlear stimulator can treat hearing loss in a variety of clinical situations. Occasionally skin/scar overgrowth may cover the abutment. This overgrowth interferes with affixing the BAHA to the abutment. Surgical scar revision/excision has been used to treat this problem. Clobetasol (0.05%), a steroid gel, can reduce skin overgrowth. Experience with skin overgrowth and the efficacy of clobetasol to treat this problem was reviewed. SUBJECTS AND METHODS: The authors conducted a retrospective analysis of patients who underwent BAHA abutment implantation from January 2003 through December 2006. RESULTS: Eighty-eight patients (2 patients received bilateral BAHAs) were reviewed. Twenty (22%) of 90 sites developed overgrowth. Thirteen of 20 sites were treated with clobetasol. The overgrowth resolved in 11 (85%) of 13 sites after treatment. Patients with incomplete skin graft survival were significantly more likely to develop skin overgrowth (P = 0.0017). CONCLUSION: Clobetasol is an effective treatment for abutment skin/scar overgrowth. Clobetasol allows patients to resume BAHA use and obviates the need for scar revision.
Full Text
Duke Authors
Cited Authors
- Falcone, MT; Kaylie, DM; Labadie, RF; Haynes, DS
Published Date
- December 2008
Published In
Volume / Issue
- 139 / 6
Start / End Page
- 829 - 832
PubMed ID
- 19041511
International Standard Serial Number (ISSN)
- 0194-5998
Digital Object Identifier (DOI)
- 10.1016/j.otohns.2008.08.021
Language
- eng
Conference Location
- England